Drug Pipeline News

FDA approved norelgestromin and ethinyl estradiol (Gwyn Lo; Viatris) as a low-dose once-weekly contraceptive patch.

Natural Cycles received a sixth FDA clearance for an updated version of its fertility-tracking algorithm.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Roche's cobas BV/CV assay received FDA clearance as a single-swab test for bacterial vaginosis and candida vaginitis.

Connor Frey, MD, explains why semaglutide and tirzepatide, but not liraglutide, generated menstrual adverse event signals in a FAERS pharmacovigilance analysis.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.

A look ahead to the second half of 2026 for ob-gyns, including Viatris's pending FDA decision on a low-dose estrogen contraceptive patch and previews of the IDSOG, AUGS PFD Week, and The Menopause Society annual meetings.

Originally approved in February 2020, levonorgestrel and ethinyl estradiol has now received FDA approval for an updated labeled strength expected to appear on the market in the fall of 2026.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.

During clinical validation done by the company, Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results in 16 samples.

These are the top 5 headlines you might have missed in April 2026 from Contemporary OB/GYN.

The expanded label to include use during pregnancy complicated by type 1 diabetes mellitus is based on data from the CIRCUIT trial.

Utepreva LLC has launched a proprietary, FDA-cleared endometrial sampler that combines suction, disruption, and absorption to improve tissue yield in 20-second office procedures.

The letter from the federal agency allows further phase 2 development for refisolone under an investigational new drug application.

Ramu Perni highlights how the "one tube" workflow streamlines obstetric practices by enabling add-on RBC and platelet antigen tests.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

The FDA cleared the Onclarity HPV Self-Collection Kit, allowing patients to collect samples at home for processing via the FDA-cleared BD Onclarity HPV Assay and BD COR System.

The Ringza slow-release vaginal ring has launched in Canada and is designed to be re-used for up to 1 year.

Researchers developed a porous membrane organ-on-a-chip that replicates the human cervix to study how the microbiome and immune system interact with chlamydia and gonorrhea.

Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.